For laboratory and research use only. Not for human consumption.
peptibase.
Bioregulators

Cardiogen

Also known as: AEDR, Ala-Glu-Asp-Arg, H-Ala-Glu-Asp-Arg-OH

Preclinical
Share:
Last reviewed

Buy in shop

Cardiogen

2 verified vendors, side by side on real prices.

Compare prices

Key Facts: Cardiogen

Category
Bioregulators
FDA Status
Not FDA Approved
Clinical Status
Preclinical research only. Not approved by the FDA, EMA, or any major regulator for any indication. Not named on the 2026 WADA Prohibited List, but as a substance with no human therapeutic approval it falls under WADA's catch-all S0 (Non-approved substances), prohibited at all times for tested athletes. Russian supplement status not independently verified.
Banned in Sport (WADA)
Not named on the WADA list. Its Russian registration may not count as drug approval (many Khavinson bioregulators are sold as supplements), so WADA's S0 catch-all may cover it; treat it as a risk.
Administration
Intraperitoneal or intramuscular injection in rats
Typical Dose
No established human dose
Frequency
Not established
Duration
Single doses to 10 days in animal models
Also Known As
AEDR, Ala-Glu-Asp-Arg, H-Ala-Glu-Asp-Arg-OH

How does Cardiogen work?

Like the rest of the Khavinson line, Cardiogen is proposed to work at the level of gene expression rather than through a classic receptor. The group's in-vitro work reports that AEDR binds histone proteins (H1, H2B, H3 and H4) and can either speed up or slow down how certain endonucleases cut DNA, depending on DNA methylation. The idea is that this opens up gene promoter regions and nudges heart and blood-vessel cells toward 'younger' expression patterns. The patent also describes increased growth of cultured rat heart tissue explants, which the authors read as a proliferative effect. All of this comes from one research group, and none of it has been independently replicated, so treat the mechanism as a hypothesis.

What does the research show?

There is not much to work with. The main primary source is US patent 7,662,789 (Khavinson and colleagues, priority 2004), which reports rat and guinea pig experiments: in rats with a tied-off coronary artery, three tiny injections (0.05 micrograms per animal) cut 24-hour mortality from 45% to 15% and shrank the dead-tissue zone; it also reports better recovery of isolated guinea pig hearts after ischemia, less damage in adrenaline-induced and toxin-induced heart injury, and fewer deaths in a calcium chloride arrhythmia model, with 0.2 micrograms per kg working best. A 2021 systematic review by the same group in Molecules lists AEDR as a peptide for 'regulation of cardiovascular system function', but the supporting data cited are histone-binding and DNA-cleavage experiments in a test tube, not heart studies. Patents report the inventor's own results, are not peer reviewed in the usual sense, and have not been repeated by outside labs. No human trials, no pharmacokinetics in people, no long-term safety data. If someone tells you Cardiogen repairs heart muscle in humans, they are well ahead of the evidence.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

What doses have been studied?

Preclinical·Rat studies and in-vitro data from one research group, mostly via patent

Note: Animal study doses may not translate directly to humans.

Typical Dosingⓘ

Community experience

Common Dose

No established human dose

Range

Not established in any published study

Frequency

Not established

Khavinson-style bioregulators are usually run as short courses (10-30 days), but no published study has tested any human dose of Cardiogen. The only real dosing data are microgram-per-kg amounts in rats.

Research Dosingⓘ

Scientific studies

Doses from animal studies only. No published human dosing exists.

Duration

Single doses to 10 days in animal models

Administration

Intraperitoneal or intramuscular injection in rats

When and how is Cardiogen taken?

Best Time to Take

Morning on empty stomach (bioregulator convention, not tested)

Once daily in short courses, per bioregulator convention

Food Recommendation

Take on empty stomach

Why This Timing?

There is no human pharmacology data for Cardiogen. The morning fasted habit comes from how Khavinson bioregulators are generally used, not from any Cardiogen study.

What are the side effects of Cardiogen?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●No human safety data published
  • ●Animal toxicity testing in the patent reported no toxic effects at doses far above the active dose
  • ●Raised white blood cell counts in a 6-month guinea pig study (patent data)
  • ●Injection site reactions possible with injectable forms
  • ●Product purity and identity are unverified for research-grade material
  • ●Not a substitute for real cardiac care

References

Research This Peptide Further

PubMedClinicalTrials.govFDA.gov

Buy in shop

Cardiogen

2 verified vendors, side by side on real prices.

Compare prices

Frequently Asked Questions

What does Cardiogen do?

Cardiogen is a synthetic tetrapeptide, Ala-Glu-Asp-Arg (AEDR), from Vladimir Khavinson's family of short peptide bioregulators, pitched as the heart and cardiovascular peptide. It is a research compound, not an approved drug anywhere we could verify. Honest take: the published evidence is very thin, mostly a Khavinson patent with rat experiments and a few in-vitro binding studies from the same group, and there are no registered human trials.

How does Cardiogen work?

Like the rest of the Khavinson line, Cardiogen is proposed to work at the level of gene expression rather than through a classic receptor. The group's in-vitro work reports that AEDR binds histone proteins (H1, H2B, H3 and H4) and can either speed up or slow down how certain endonucleases cut DNA, depending on DNA methylation. The idea is that this opens up gene promoter regions and nudges heart and blood-vessel cells toward 'younger' expression patterns. The patent also describes increased growth of cultured rat heart tissue explants, which the authors read as a proliferative effect. All of this comes from one research group, and none of it has been independently replicated, so treat the mechanism as a hypothesis.

Is Cardiogen FDA approved?

No, Cardiogen is not currently FDA approved. Current status: Preclinical research only. Not approved by the FDA, EMA, or any major regulator for any indication. Not named on the 2026 WADA Prohibited List, but as a substance with no human therapeutic approval it falls under WADA's catch-all S0 (Non-approved substances), prohibited at all times for tested athletes. Russian supplement status not independently verified.

Is Cardiogen banned in sport?

Not named on the WADA list. Its Russian registration may not count as drug approval (many Khavinson bioregulators are sold as supplements), so WADA's S0 catch-all may cover it; treat it as a risk.

What are the side effects of Cardiogen?

Reported side effects include: No human safety data published, Animal toxicity testing in the patent reported no toxic effects at doses far above the active dose, Raised white blood cell counts in a 6-month guinea pig study (patent data), Injection site reactions possible with injectable forms, Product purity and identity are unverified for research-grade material. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Cardiogen?

Community-reported common dose: No established human dose (Not established). Range: Not established in any published study. Administration: Intraperitoneal or intramuscular injection in rats. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Cardiogen or used in similar applications.

Livagen

Preclinical

Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.

Bioregulators

Ovagen

Preclinical

Ovagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.

Bioregulators

Cortagen

Preclinical

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.

Bioregulators

Vesugen

Preclinical

Vesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.

Bioregulators

Chonluten

Preclinical

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.

Bioregulators

Crystagen

Preclinical

Crystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).

Bioregulators
How to Use CardiogenCardiogen AlternativesCompare with SimilarBrowse All Peptides

Want updates on Cardiogen research?

Get an email when we add new research here, when it is back in stock, or when the price drops.

Back to all peptides